ArticleFrontiers in oncology2025

Ensartinib as a neoadjuvant therapy for stage IIIA non-small cell lung cancer patients with EML4-ALK fusion: a case report and literature review.

Hao Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.